Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus

Shazia Naheed,1 Irum Umar Din,1 Muhammad Usman Qamar,2 Nasir Rasool,1 Matloob Ahmad,1 Muhammad Bilal,1 Aqsa Khalid,3 Gulraiz Ahmad,1 Sami A Al-Hussain,4 Magdi EA Zaki4 1Department of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan; 2Institute of Microbiology, Faculty...

Full description

Bibliographic Details
Published in:Infection and Drug Resistance
Main Authors: Naheed,Shazia, Din,Irum Umar, Qamar,Muhammad Usman, Rasool,Nasir, Ahmad,Matloob, Bilal,Muhammad, Khalid,Aqsa, Ahmad,Gulraiz, Al-Hussain,Sami A, Zaki,Magdi EA
Format: Article in Journal/Newspaper
Language:English
Published: Dove Press 2023
Subjects:
Online Access:https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR
id ftdovepress:oai:dovepress.com/85876
record_format openpolar
spelling ftdovepress:oai:dovepress.com/85876 2023-09-05T13:22:56+02:00 Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus Naheed,Shazia Din,Irum Umar Qamar,Muhammad Usman Rasool,Nasir Ahmad,Matloob Bilal,Muhammad Khalid,Aqsa Ahmad,Gulraiz Al-Hussain,Sami A Zaki,Magdi EA 2023-08-14 text/html https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/IDR.S407891 https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR info:eu-repo/semantics/openAccess Infection and Drug Resistance Original Research info:eu-repo/semantics/article 2023 ftdovepress https://doi.org/10.2147/IDR.S407891 2023-08-20T17:36:40Z Shazia Naheed,1 Irum Umar Din,1 Muhammad Usman Qamar,2 Nasir Rasool,1 Matloob Ahmad,1 Muhammad Bilal,1 Aqsa Khalid,3 Gulraiz Ahmad,1 Sami A Al-Hussain,4 Magdi EA Zaki4 1Department of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan; 2Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000, Pakistan; 3School of Interdisciplinary Engineering & Science (SINES), National University of Sciences and Technology (NUST), Islamabad, 44000, Pakistan; 4Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University, Riyad, 11623, Saudi ArabiaCorrespondence: Nasir Rasool; Magdi E A Zaki, Email nasirrasool@gcuf.edu.pk; mezaki@imamu.edu.saIntroduction: Global public health concerns include the emergence and spread of methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase Escherichia coli (ESBL-E. coli). These pathogens cause infections that are difficult to treat, which can have fatal outcomes and require lengthy hospital stays. As a result, we created butyl 2-bromoisonicotinate and tested its antibacterial effectiveness against the ESBL-E. coli ST 405 and MRSA pathogens. Natural product discovery is complemented by synthetic compound synthesis because of the latter’s potential for superior characteristics, target specificity, scalability, intellectual advantages, and chemical diversity. Because of this, the potential for discovering new medicinal compounds is increased, and the constraints placed on natural sources are overcome. Natural items are tough to obtain since they are hard to isolate and synthesize. Therefore, modern science is actively searching for small molecules as therapeutic agents by applying sustainable techniques that can be commercialized.Methods: Two patients’ blood samples were taken, and the BACTEC/Alert system was used to process them. On blood and MacConkey agar, the positive samples were subcultured and incubated aerobically at 37 °C. Using the VITEK 2 compact ... Article in Journal/Newspaper sami Dove Medical Press Infection and Drug Resistance Volume 16 5295 5308
institution Open Polar
collection Dove Medical Press
op_collection_id ftdovepress
language English
topic Infection and Drug Resistance
spellingShingle Infection and Drug Resistance
Naheed,Shazia
Din,Irum Umar
Qamar,Muhammad Usman
Rasool,Nasir
Ahmad,Matloob
Bilal,Muhammad
Khalid,Aqsa
Ahmad,Gulraiz
Al-Hussain,Sami A
Zaki,Magdi EA
Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus
topic_facet Infection and Drug Resistance
description Shazia Naheed,1 Irum Umar Din,1 Muhammad Usman Qamar,2 Nasir Rasool,1 Matloob Ahmad,1 Muhammad Bilal,1 Aqsa Khalid,3 Gulraiz Ahmad,1 Sami A Al-Hussain,4 Magdi EA Zaki4 1Department of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan; 2Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000, Pakistan; 3School of Interdisciplinary Engineering & Science (SINES), National University of Sciences and Technology (NUST), Islamabad, 44000, Pakistan; 4Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University, Riyad, 11623, Saudi ArabiaCorrespondence: Nasir Rasool; Magdi E A Zaki, Email nasirrasool@gcuf.edu.pk; mezaki@imamu.edu.saIntroduction: Global public health concerns include the emergence and spread of methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase Escherichia coli (ESBL-E. coli). These pathogens cause infections that are difficult to treat, which can have fatal outcomes and require lengthy hospital stays. As a result, we created butyl 2-bromoisonicotinate and tested its antibacterial effectiveness against the ESBL-E. coli ST 405 and MRSA pathogens. Natural product discovery is complemented by synthetic compound synthesis because of the latter’s potential for superior characteristics, target specificity, scalability, intellectual advantages, and chemical diversity. Because of this, the potential for discovering new medicinal compounds is increased, and the constraints placed on natural sources are overcome. Natural items are tough to obtain since they are hard to isolate and synthesize. Therefore, modern science is actively searching for small molecules as therapeutic agents by applying sustainable techniques that can be commercialized.Methods: Two patients’ blood samples were taken, and the BACTEC/Alert system was used to process them. On blood and MacConkey agar, the positive samples were subcultured and incubated aerobically at 37 °C. Using the VITEK 2 compact ...
format Article in Journal/Newspaper
author Naheed,Shazia
Din,Irum Umar
Qamar,Muhammad Usman
Rasool,Nasir
Ahmad,Matloob
Bilal,Muhammad
Khalid,Aqsa
Ahmad,Gulraiz
Al-Hussain,Sami A
Zaki,Magdi EA
author_facet Naheed,Shazia
Din,Irum Umar
Qamar,Muhammad Usman
Rasool,Nasir
Ahmad,Matloob
Bilal,Muhammad
Khalid,Aqsa
Ahmad,Gulraiz
Al-Hussain,Sami A
Zaki,Magdi EA
author_sort Naheed,Shazia
title Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus
title_short Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus
title_full Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus
title_fullStr Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus
title_full_unstemmed Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus
title_sort synthesis, anti-bacterial and molecular docking studies of arylated butyl 2-bromoisonicotinate against clinical isolates of esbl-producing escherichia coli st405 and methicillin-resistant staphylococcus aureus
publisher Dove Press
publishDate 2023
url https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR
genre sami
genre_facet sami
op_relation info:eu-repo/semantics/altIdentifier/doi/10.2147/IDR.S407891
https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR
op_rights info:eu-repo/semantics/openAccess
op_doi https://doi.org/10.2147/IDR.S407891
container_title Infection and Drug Resistance
container_volume Volume 16
container_start_page 5295
op_container_end_page 5308
_version_ 1776203509173059584